|
|
||||||||
J Thorac Cardiovasc Surg 1998;115:681-685
© 1998 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St. Louis, Mo., and (*current address) the Division of Cardiovascular and Thoracic Surgery, Department of Surgery, University of Southern California, Los Angeles, Calif.
Received for publication April 10, 1997; revisions requested July 15, 1997; revisions received Oct. 16, 1997; accepted for publication Oct. 16, 1997. Address for reprints: Joel D. Cooper, MD, Division of Cardiothoracic Surgery, Washington University School of Medicine, One Barnes Hospital Plaza, 3108 Queeny Tower, St. Louis, MO 63110.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
We have previously reported the beneficial early and intermediate-term results of lung volume reduction (LVR) in 150 selected patients with advanced emphysema.
5,6 In 10% of these patients a complete, anatomic lobectomy was included in the bilateral procedure because the entire lobe was destroyed by emphysema and the anatomic findings at operation were favorable for a lobectomy. Interestingly, pathologic examination of resected lung tissue in 2 of the 150 patients revealed a focus of cancer not detected preoperatively. Subsequently, five patients were seen with suspected or proven lung cancer and severe emphysema anatomically amenable to LVR. In each patient the respiratory compromise from emphysema was so severe that under previous selection criteria none of them would have been considered suitable candidates for a major pulmonary resection. Furthermore, in each patient the lung cancer was situated such that wedge excision would be difficult or impossible. However, given the demonstrated benefits of LVR in patients with a suitable anatomic situation, and the lack of satisfactory alternative treatment in these select patients with lung cancer, we chose to perform a cancer resection with anatomic lobectomy in conjunction with LVR. The purpose of this report is to describe these cases and the early postoperative results.
| Methods |
|---|
|
|
|---|
The mean age of the five patients was 62 years (range 53 to 70 years), and three were men. None of the patients had symptoms from the cancer, but all had symptoms of advanced emphysema. Two patients had dyspnea at rest (patients c and d) and required continuous supplemental oxygen. One patient (patient d) was receiving 30 mg/day of prednisone when first evaluated but was weaned to 5 mg/day before operation. A preoperative diagnosis of cancer was made in four patients (all except patient a). Evaluation in each patient included inspiratory and expiratory posteroanterior and lateral chest x-ray films, chest computed tomographic scans including views of the liver and adrenal glands, and a ventilation/perfusion scan. A representative chest x-ray film and a ventilation/perfusion scan from one patient (patient a) are shown in Fig. 1. Candidates for combined lobectomy and volume reduction had to have radiographic and scintigraphic evidence of severe emphysema in a heterogeneous distribution. Furthermore, the pulmonary nodule had to be located in one of the more destroyed lobes. Evaluation of each patient also included pulmonary function tests (PFTs), an arterial blood gas, and a 6-minute walk test (Table I). Systemic staging consisted of a brain computed tomogram and radionucleotide bone scan in each patient. A noninvasive cardiac evaluation was done before the operation as a standard procedure. One patient (patient e) was found to have coronary artery disease and ultimately required angioplasty before undergoing pulmonary resection. In another patient (patient c), a prior myocardial infarction resulted in a reduced left ventricular ejection fraction (26%), but no areas of active ischemia were identified. No other nonpulmonary organ dysfunction was identified in these patients.
|
|
At operation, each patient underwent bronchoscopy, and four of the five patients had mediastinoscopy. One patient (patient a) had a small, undiagnosed right upper lobe lung nodule with no computed tomographic evidence of mediastinal adenopathy, and she did not undergo mediastinoscopy. A median sternotomy was used in four of the five patients. One patient (patient d) had previously undergone bleb excision and pleurectomy on the left side because of recurrent spontaneous pneumothorax, and he underwent bilateral staged thoracotomies. Pleural tents were used to eliminate residual intrathoracic space after resection in two of the five patients. The operative procedure and pathologic stage of the resected tumor for each patient are shown in Table II.
|
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
A number of studies have examined the relationship of preoperative PFT findings and operative outcome in an attempt to predict perioperative risk for a patient requiring pulmonary resection and to define criteria for inoperability. In 1971 Boushy and associates
10 reported that of all the PFT values, FEV1 was the most helpful in selecting patients at high risk for postoperative mortality. Miller, Grossman, and Hatcher
11 in 1981 and Miller
12 in 1993 published findings from a series of 1831 pulmonary resections, including 785 lobectomies and 161 pneumonectomies, which were done with an overall operative mortality rate of 0.65%. In this series, the minimum criteria for lobectomy were a maximal voluntary ventilation greater than 40% of predicted, an FEV1 value greater than 1 L, and an FEV25-75 value of greater than 0.6 L. Ferguson and colleagues,
13 on the other hand, analyzed PFT data from 237 patients who underwent pulmonary resection and determined that the most important predictor of death and pulmonary complications was the corrected diffusing capacity as a percentage of predicted. They recommended that patients in whom this value was less than 60% be excluded from consideration for major pulmonary resection.
In an effort to further define the operative risk in patients with marginal PFT findings, Olsen and Block,
14 Kristersson,
15 Ali,
16 Wernly,
17 and their associates have reported on methods to quantify differential lung function on the basis of xenon 133 ventilation radiospirometry with or without technetium 99 perfusion scanning. In the series by Wernly and coworkers,
17 patients with a predicted postresection FEV1 value of less than 1 L were considered unfit for resection. Others have suggested that the loss of pulmonary vascular compliance or an impaired maximal oxygen consumption during exercise will help define patients at high risk for resection.
Despite the multitude of methods to assess perioperative risk for resection, the fact remains that no single test, number, or percentage has been demonstrated to reliably separate patients who will tolerate resection from those who will not. Rather, most thoracic surgeons rely on several of these tests, in addition to the overall physical state of the patient, to select operative candidates. With the development of LVR operations, however, patients with advanced emphysema who do not meet traditional PFT and clinical criteria for pulmonary resection have undergone resection of 20% to 40% of the volume of each lung and have shown remarkable postoperative improvement in both symptoms and measured pulmonary function.
18 Postulated mechanisms include an improvement in elastic recoil of the lung; reduced airway resistance; an improvement in diaphragmatic function, chest wall mechanics, and respiratory muscle efficiency; and an overall reduction in ventilation/perfusion mismatch.
18-20
Having established a successful volume reduction program, and having gained experience with the perioperative treatment of patients with advanced emphysema, it seemed logical to extend the benefits of the volume reduction concept to a select group of patients with the combination of early-stage lung cancer and severe emphysema. Patients whose disease might otherwise be considered inoperable could potentially undergo an optimal cancer operation with anatomic lobectomy and simultaneously achieve an overall improvement in respiratory status. This is precisely what has occurred in this early series of patients, each of whom had PFT values that in one or more categories fell well below the traditionally accepted minimal criteria for lobectomy. Consistent with reports on patients who have undergone volume reduction operation alone, each of these patients had postoperative improvement in the PFT findings, with an increase in FEV1 and a decrease in the total lung capacity and residual volume. These objective improvements in measured pulmonary function correlated with improvement in each patients' symptoms of dyspnea and with an improvement in the 6-minute walk distance in four of the five patients.
It is important to recognize that in these selected patients, as a consequence of the heterogeneous distribution of the emphysema, anatomic lobectomy was accomplished without any patient having a decrease in FEV1 values after resection. Furthermore, the PFT improvements have persisted in the postoperative period, although a slow return toward the preoperative values is apparent in the one patient with 2-year follow-up. This steady decline likely represents the natural history of severe emphysema, with gradual deterioration of the remaining emphysematous lung tissue. This finding reinforces the concept that volume reduction operations may "set the clock back" for patients with advanced emphysema but do not cure them of the disease.
As with any volume reduction operation, we believe that a combined cancer and volume reduction operation should be offered only to a very select group of patients. Specifically, ideal candidates for a combined operation would have symptomatic emphysema with hyperinflated lungs and target areas of severe destruction, with the cancer located in a target lobe. Two of our patients were not ideal in that the cancer was in the middle lobe, whereas the most destroyed lung was in the upper lobes. However, middle lobectomy in combination with upper lobe volume reduction was well tolerated in each patient despite the loss of some functioning middle lobe lung parenchyma. In some patients a lobectomy alone may suffice both for the cancer operation and the volume reduction effect. Indeed, anecdotal reports have circulated for years among thoracic surgeons about patients with severe emphysema who believed they were able to breathe better after a lobectomy, usually of an upper lobe, done because of lung cancer. Patients with significant emphysema and cancer located in the areas of best-preserved lung, however, would not be candidates for a lobectomy. In this circumstance one might consider a wedge or segmental excision of the cancer concomitant with LVR. Although this approach leads to an increased risk of local recurrence, in suitable candidates it likely would leave the patient with a better respiratory status and a better chance of cure than would primary radiation therapy. Radiation therapy, in nearly all circumstances, will leave the patient with worse pulmonary function than they had at the onset of treatment. Surgical resection, in appropriate candidates, not only offers the best chance for cure but is also the only treatment modality with the potential to improve the patients' respiratory status after therapy. As such, operation should be considered in patients with an appropriate anatomic situation regardless of the degree of impairment in measured PFTs. In this series, patients were carefully screened for the presence of comorbid conditions. Likely, the presence of nonpulmonary organ dysfunction would greatly increase the operative risks in these patients and should be factored into the decision on how to treat the lung cancer.
A number of issues remain unresolved. It has been our policy not to consider LVR in any patient who has smoked cigarettes within the previous 6 months. Furthermore, we insist on a period of preoperative pulmonary rehabilitation, usually for 8 weeks, with the goal of maximizing exercise endurance and capacity. To what extent these requirements should be altered in patients with coexisting lung cancer remains undetermined. Review of our experience with structured pulmonary rehabilitation in patients undergoing LVR has shown that with preoperative rehabilitation patients improve their 6-minute walk distance an average of 30% to 40% over the distance at the time of evaluation. In this group of five patients, four had preoperative rehabilitation, and two of these patients demonstrated improvement in 6-minute walk distance. One patient was found to be severely deconditioned at evaluation and with 8 weeks of rehabilitation increased his 6-minute walk distance by 2725% (from 40 feet to 1090 feet). Clearly, patients in the worst cardiorespiratory condition at the time of evaluation stand to gain the most with preoperative rehabilitation, whereas the gains in those in better condition initially are likely to be marginal. Indeed, one of the five patients in this report was judged at evaluation to be fit and did well without any preoperative rehabilitation. Furthermore, the two patients who had 6-minute walk distances greater than 1000 feet at evaluation did not show any improvement with structured pulmonary rehabilitation. Thus delay in resection for rehabilitation is probably only justified in the most deconditioned patients, and perhaps the 6-minute walk test might prove to be a helpful discriminator to determine who might benefit most from preoperative structured pulmonary rehabilitation. Currently, however, a minimum of several weeks of smoking cessation and exercise rehabilitation would, in our opinion, seem essential in many of these patients.
In summary, we believe that the introduction of volume reduction operations has added a new arm in the algorithm for the evaluation and treatment of lung cancer in patients with advanced emphysema. In this report we have demonstrated that within the group of patients with both emphysema and lung cancer there exists a subset of patients whose disease is anatomically suitable for a combined lobectomy and volume reduction. This combination not only allows an optimal cancer resection in patients who might otherwise be considered inoperable, but also in appropriately selected patients results in improved postoperative subjective and objective pulmonary function. Thus patients with lung cancer and poor PFT findings should not automatically be labeled as unfit for resection. Rather, given the propensity for both emphysema and lung cancer to occur in patients with a significant smoking history, it is likely that a combined approach could be applicable to a significant number of patients. Undoubtedly, further experience with LVR operations, both alone and in combination with a cancer operation, will help refine the indications, contraindications, and limitations of such an approach.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Patel, M. DeCamp, and G. J. Criner Lung Transplantation and Lung Volume Reduction Surgery versus Transplantation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 447 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. L. Colice, S. Shafazand, J. P. Griffin, R. Keenan, and C. T. Bolliger Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 161S - 177S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Varela, A. Brunelli, G. Rocco, M. F. Jimenez, M. Salati, and T. Gatani Evidence of Lower Alteration of Expiratory Volume in Patients With Airflow Limitation in the Immediate Period After Lobectomy Ann. Thorac. Surg., August 1, 2007; 84(2): 417 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E Martin-Ucar, K. R Fareed, A. Nakas, P. Vaughan, J. G Edwards, and D. A Waller Is the initial feasibility of lobectomy for stage I non-small cell lung cancer in severe heterogeneous emphysema justified by long-term survival? Thorax, July 1, 2007; 62(7): 577 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Baldi, E. Ruffini, S. Harari, G. C. Roviaro, M. Nosotti, N. Bellaviti, F. Venuta, D. Diso, F. Rea, C. Schiraldi, et al. Does lobectomy for lung cancer in patients with chronic obstructive pulmonary disease affect lung function? A multicenter national study J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1616 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Matsuoka, Y. Kurihara, K. Yagihashi, H. Niimi, and Y. Nakajima Peripheral Solitary Pulmonary Nodule: CT Findings in Patients with Pulmonary Emphysema Radiology, April 1, 2005; 235(1): 266 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Choong, B. F. Meyers, R. J. Battafarano, T. J. Guthrie, G. E. Davis, G. A. Patterson, and J. D. Cooper Lung cancer resection combined with lung volume reduction in patients with severe emphysema J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1323 - 1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pompeo, E. De Dominicis, V. Ambrogi, D. Mineo, S. Elia, and T. C. Mineo Quality of life after tailored combined surgery for stage I non-small-cell lung cancer and severe emphysema Ann. Thorac. Surg., December 1, 2003; 76(6): 1821 - 1827. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Burke, I. G. Duarte, V. H. Thourani, and J. I. Miller Jr Preoperative risk assessment for marginal patients requiring pulmonary resection Ann. Thorac. Surg., November 1, 2003; 76(5): 1767 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sekine, T. Iwata, M. Chiyo, K. Yasufuku, S. Motohashi, S. Yoshida, M. Suzuki, T. Iizasa, Y. Saitoh, and T. Fujisawa Minimal alteration of pulmonary function after lobectomy in lung cancer patients with chronic obstructive pulmonary disease Ann. Thorac. Surg., August 1, 2003; 76(2): 356 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fujimoto, H. Teschler, L. Hillejan, G. Zaboura, and G. Stamatis Long-term results of lung volume reduction surgery Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 483 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Santambrogio, M. Nosotti, A. Baisi, G. Ronzoni, N. Bellaviti, and L. Rosso Pulmonary lobectomy for lung cancer: a prospective study to compare patients with forced expiratory volume in 1 s more or less than 80% of predicted Eur. J. Cardiothorac. Surg., October 1, 2001; 20(4): 684 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
J G Edwards, D J R Duthie, and D A Waller Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema Thorax, October 1, 2001; 56(10): 791 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Ambrogi, E. Pompeo, G. Matteucci, and T. C. Mineo Combined surgery for emphysema and lung cancer Eur. J. Cardiothorac. Surg., September 1, 2000; 18(3): 372 - 374. [Full Text] [PDF] |
||||
![]() |
A. Carretta, P. Zannini, A. Puglisi, G. Chiesa, A. Vanzulli, A. Bianchi, A. Fumagalli, and S. Bianco Improvement of pulmonary function after lobectomy for non-small cell lung cancer in emphysematous patients Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 602 - 607. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |